Published Work on liquisolid technology

Patents
1) LIQUISOLID SYSTEMS AND METHODS OF PREPARING SAME (WO/1997/047290)
Spireas S and Bolton S.

2) Liquisolid systems and methods of preparing same. Spireas S and Bolton S.
US Patent 6423339

3) Spireas S, Bolton M. Liquisolid Systems and Methods of Preparing Same. U.S. Patent 6,096,337; 2000.

Published Journal articles
1) Liquisolid technology for dissolution rate enhancement or sustained release.  Karmarkar AB; Gonjari ID; Hosmani AH. Expert Opinion on Drug Delivery. http://informahealthcare.com/doi/abs/10.1517/17425247.2010.511173

2)Spireas S, Sadu S. Enhancement of prednisolone dissolution properties using liquisolid compacts. Int J Pharm. 1998; 166: 177–188.

3)S. Spireas, T. Wang, R. Grover, E.ect of powder substrate on the dissolution properties of  methchrothiazide liquisolid compacts, Drug Dev. Ind. Pharm. 25 (2) (1999) 163–168.

4) S. Spireas, S. Sadu, R. Grover, In-vitro release evaluation of hydrocortisone liquisolid tablets, J. Pharm. Sci. 87 (7) (1998) 867–872.

5)Y. Javadzadeh, M.R. Siahi-Shadbad, M. Barzegar-Jalali, A. Nokhodchi, Enhancement of dissolution rate of piroxicam using liquisolid compacts, Il Farmaco 60 (2005) 361–365.

6)Nokhodchi A, The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts, J. Pharm. Pharma. Sci. 8 (1) (2005) 18–25.

7) Khaled KA, Asiri YA, El-Sayed YM. In vivo evaluation of liquisolid tablets in beagle dogs. Int. J. Pharm. 222(2001) 1-6.

8) Khaled KA. Formulation and evaluation of hydrochlorothiazide liquisolid tablets. Saudi Pharm. J. 6(1988) 39-46.

9)Karmarkar AB, Gonjari ID, Hosmani AH, Dhabale PN. Evaluation of in vitro dissolution profile comparison methods of sustained release tramadol hydrochloride liquisolid compact formulations with marketed sustained release tablets. Drug Discoveries and Therapeutics. 2010, 4 (1), 26 – 32. 

10)Karmarkar AB, Gonjari ID, Hosmani AH, Dhabale PN, Bhise SB. Dissolution rate enhancement of Fenofibrate using liquisolid tablet technique Part II: Evaluation of in vitro dissolution profile comparison methods. Latin American Journal of Pharmacy [Formerly Acta Farmaceutica Bonaerense]) 2009, 28 (4), 538-43.  

11) Karmarkar AB, Gonjari ID, Hosmani AH, Dhabale PN, Bhise SB. Dissolution rate enhancement of Fenofibrate using liquisolid tablet technique. Latin American Journal of Pharmacy [Formerly Acta Farmaceutica Bonaerense] 2009, 28 (2)219-225. 



http://www.latamjpharm.org/trabajos/28/2/LAJOP_28_2_1_8_SLMR1NB89L.pdf

12)Karmarkar AB, Gonjari ID, Hosmani AH, Dhabale PN, Bhise SB. Liquisolid tablets: A novel approach for drug delivery. International Journal of Health Research, 2009, 2 (1), 45-50 (e2111p93-98).

13) S. Spireas, T. Wang, R. Grover, E.ect of powder substrate on the dissolution properties of methchrothiazide liquisolid compacts, Drug Dev. Ind. Pharm. 25 (2) (1999) 163–168.

14)S. Spireas, S. Sadu, R. Grover, In-vitro release evaluation of hydrocortisone liquisolid tablets, J. Pharm. Sci. 87 (7) (1998) 867–872.

15) Kulkarni AS; Gaja JB.Formulation and Evaluation of Liquisolid Compacts of Diclofenac Sodium. PDA Journal of Pharmaceutical Science and Technology. http://journal.pda.org/content/64/3/222.abstract


16)Ali Nokhodchi; Roya Aliakbar; Sandip Desai; Yousef Javadzadeh. Liquisolid compacts: the effect of cosolvent and HPMC on theophylline release.Colloids and surfaces. B, Biointerfaces. 2010 Aug

17) Karmarkar AB, Effect of Ceolus KG-802 on the dissolution rate of fenofibrate liquisolid tablets: Preformulation and formulation development studies. Drug Discov Ther. 2010 ;4(6):493-498
http://www.ddtjournal.com/getabstract.php?id=394